Boai NKY Medical Holdings (300109) Fair Value & Analysis
Basic Materials · CN · Market cap 8.5B CNY
Fair value as of: Jun 24, 2026
Analysis
Boai NKY Medical Holdings (300109) currently trades at ¥15.51, while our model-based Fair Value estimate is ¥6.69 — implying the stock looks roughly 56.9% overvalued today. We read business quality at 94/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP), Orarez, and in vitro diagnostic products, as well as invests in tumor drugs. It offers its products for pharmaceutical products, such as APIs and excipients; personal care products, including cosmetics, haircare, oral care, and household care; alcohol, soft drinks, and food; battery, petroleum and natural gas, and photovoltaic; and membrane, textile and dyeing, agriculture, stationery, semiconductor, and other industries. The company was formerly known as Boai NKY Pharmaceuticals Ltd. and changed its name to Boai NKY Medical Holdings Ltd. in March 2016. Boai NKY Medical Holdings Ltd. was founded in 1987 and is based in Jiaozuo, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Boai NKY Medical Holdings (300109) undervalued?
What is the fair value of 300109?
What is the quality score of 300109?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.